Protocol Ledger

NCT07003074 · Phase III · RECRUITING

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT07003074 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-23 Enrollment: 642 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07003074
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)642 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07003074
Protocol FieldVerified Registry Value
NCT IdentifierNCT07003074
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment642 participants (ESTIMATED)
Registered Start Date2025-06-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07003074
Hospital Research SiteLocationSite Profile
Anhui Provincial Cancer HospitalHefei, ChinaOpen Hospital Dossier ->
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Beijing Tiantan Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI